Tango Therapeutics, Inc. (TNGX)

NASDAQ: TNGX · IEX Real-Time Price · USD
8.30 -0.29 (-3.38%)
Jan 21, 2022 4:00 PM EST - Market closed

Income Statement (Annual)

Millions USD. Fiscal year is Jan - Dec.
Year20202019
Revenue
7.6624.65
Revenue Growth (YoY)
-68.94%-
Gross Profit
7.6624.65
Selling, General & Admin
9.877.54
Research & Development
49.9932.27
Operating Expenses
59.8639.81
Operating Income
-52.2-15.16
Other Expense / Income
-0.23-1.07
Pretax Income
-51.97-14.1
Net Income
-51.97-14.1
Net Income Common
-51.97-14.1
Shares Outstanding (Basic)
119
Shares Outstanding (Diluted)
119
Shares Change
27.55%-
EPS (Basic)
-4.53-1.57
EPS (Diluted)
-4.53-1.57
Free Cash Flow Per Share
6.02-2.96
Gross Margin
100.00%100.00%
Operating Margin
-681.82%-61.51%
Profit Margin
-678.84%-57.18%
Free Cash Flow Margin
900.84%-108.00%
EBITDA
-51.25-13.45
EBITDA Margin
-669.46%-54.57%
EBIT
-51.97-14.1
EBIT Margin
-678.84%-57.18%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).